Joseph Truitt, iECURE CEO
April 4, 2024 07:00 AM EDTUpdated April 5, 09:46 AM
R&D
Cell/Gene Tx

Ex­clu­sive: Jim Wil­son start­up gets FDA green light for first test of gene edit­ing in ba­bies

Ryan Cross

Senior Science Correspondent

Near­ly 25 years ago, a young man with an in­her­it­ed liv­er dis­ease died from a vi­cious im­mune re­ac­tion to an ex­per­i­men­tal gene ther­a­py. Now Jim …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

A service from the Financial Times